Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
23.04
-1.48 (-6.04%)
At close: Jul 10, 2026, 4:00 PM EDT
23.04
0.00 (0.00%)
After-hours: Jul 10, 2026, 4:10 PM EDT
Monte Rosa Therapeutics Revenue
Monte Rosa Therapeutics had revenue of $4.21M in the quarter ending March 31, 2026, a decrease of -95.04%. This brings the company's revenue in the last twelve months to $42.95M, down -73.07% year-over-year. In the year 2025, Monte Rosa Therapeutics had annual revenue of $123.67M with 63.54% growth.
Revenue (ttm)
$42.95M
Revenue Growth
-73.07%
P/S Ratio
45.31
Revenue / Employee
$229,695
Employees
187
Market Cap
1.95B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 123.67M | 48.05M | 63.54% |
| Dec 31, 2024 | 75.62M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lakefront Biotherapeutics NV | 1.20B |
| ADMA Biologics | 509.86M |
| Nuvation Bio | 143.05M |
| Recursion Pharmaceuticals | 66.41M |
| Stoke Therapeutics | 32.08M |
| Precigen | 31.60M |
| Generate Biomedicines | 30.30M |
| Taysha Gene Therapies | 7.47M |
GLUE News
- 8 days ago - Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 10 days ago - Monte Rosa Therapeutics price target raised, named a ‘top pick’ at Guggenheim - TheFly
- 5 weeks ago - Monte Rosa Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 6 weeks ago - Monte Rosa Therapeutics Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Transcripts
- 7 weeks ago - Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics price target raised to $31 from $30 at JPMorgan - TheFly
- 2 months ago - Monte Rosa Therapeutics reports Q1 revenue $4.21M, consensus $11.39M - TheFly
- 2 months ago - Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates - GlobeNewsWire